Loading company financials…
Nasdaq · Pharmaceutical Preparations · CIK 0001178670
$266.11
+12.24% · delayed 15 min
$35.23B market value
What this company does
ALNYLAM PHARMACEUTICALS develops and makes medicines. It took in $3.71B last year, which makes it a mid-sized company. Of every dollar it sells, about 8 cents is left as profit.
Financial health
Generally healthy, with a few things to watch.
From ALNYLAM PHARMACEUTICALS, INC.'s FY2025 annual filing · share price scored separately
Every check behind the three models, and what each one tests
Measured against FY2024, from the 10-K
Improved: +65.2%
$2.25B to $3.71B
Improved: turned positive
-$278.2M to $313.7M
Deteriorated: −4.6 pts
86.4% to
It makes a profit rather than burning through money.
$313.7M earned last year
Day-to-day operations generate real cash, not just accounting profit.
$524.1M cash from operations
Sales are growing quickly.
up 65.2% on last year
A widely used bankruptcy-risk model places it well clear of distress.
Altman Z 4.88
Nothing in the filings stands out as a concern.
Filter by minute, hour, day or week
Loading price history…
Expectations
Not from the filings — what other people are betting on, and what the price already assumes.
The growth rate someone buying today is paying for, against what the company has delivered
At today's price, the market is paying for free cash flow to grow by about 23% a year for the next 10 years. Over the last 2 years it grew by about 233% a year.
The essentials
Each answered from the filings, with the numbers behind it.
Yes. It keeps about 8 cents of every dollar of sales as profit, earning $313.7M last year.
What it earns, what it keeps, and what it costs to run — all from the same filing
Income
This company pays no dividend. It keeps its profits and reinvests them in the business instead, so any return would have to come from the share price.
Figures from the FY2025 annual filing
Last year it earned $313.7M and generated $524.1M of cash from operations.
Reported annual figures
Insider activity, ownership stakes and what's coming — straight from EDGAR, before any article is written about it
Estimated from how often this has happened before, not a confirmed date.
Not investment advice, and not a signal to act on by itself — a filing says what happened, not why, and insiders trade for ordinary reasons having nothing to do with where they think the company is headed.
Go deeper
Every figure above traces back to one of these filings.
Straight from SEC EDGAR — the original source for every figure above
| Filing | Filed | Covers to |
|---|---|---|
| Quarterly report(10-Q) | 2026-07-30 | 2026-06-30 |
| Major event announcement(8-K) | 2026-07-30 | 2026-07-30 |
Financial figures are from ALNY's 10-K for fiscal year 2025 (period ending 2025-12-31), reported under the US GAAP taxonomy. View the source filing.
5 of 8 checks passed
Nine yes-or-no tests of whether this year's finances improved on last year's. One could not be evaluated and is excluded from the total rather than counted as a failure.
4.88
In the safe zone
For this model, above 2.99 is safe and below 1.81 is distress.
Distance from bankruptcy, from a model fitted on companies that did and did not go bust. It describes a balance sheet's shape today; it does not forecast a failure.
not reported — This company has not reported enough of the required figures to calculate this score.
This company has not reported enough of the required figures to calculate this score.
Screens eight accounting ratios for the pattern earnings manipulators tend to leave. A flag is a reason to read the filing closely, never evidence of wrongdoing.
Every figure above comes from the FY2025 filing as filed with the SEC.
Improved: +20.8 pts
-12.4% to 8.4%
Improved: turned positive
-$42.6M to $465.4M
Improved: +71.5%
$966.4M to $1.66B
Deteriorated: +2.4%
129.3M to 132.4M
Changed: +71.2%
$34.3M to $58.7M
Figures compare the two most recent annual filings — read the latest one. Nothing here reads the management commentary, which is where a company explains its own numbers.
Discounted at 8%–10% a year, with growth settling to 2.5% after 10 years. Those rates are ordinary choices, not measurements: across that range the assumed growth works out between 20% and 25%. This describes what the price implies — it is not a forecast, and not a view on whether the price is right.
Measured on and published about a week later — this is a fortnightly snapshot, not a live position.
About 3.6% of this company's shares have been borrowed and sold by people expecting to buy them back cheaper. That is a bet the price falls. Those people can be wrong, and when a heavily shorted share rises they have to buy it back, which pushes it up further.
Collected by FINRA from broker-dealers twice a month. It counts positions, not intentions, and some of it is hedging rather than a directional bet against the company.
Nothing in this section is a figure this company reported about itself. These are expectations and positions — what the price implies, what analysts have published, what short sellers are betting, and what large funds held at the last count. WylthIQ reports them; it does not endorse them, does not forecast prices, and takes no view on whether any of them will turn out to be right.
Yes, quickly. Sales grew 65.2% last year.
It is tight. For every $1 it owes, it owns $1.19 in assets.
Expensive. Investors pay $112.3 for every $1 of yearly profit, so a lot of future growth is already priced in.
This company has not reported enough of the required figures to calculate this score.
At a glance
| Major event announcement(8-K) | 2026-05-27 | 2026-05-20 |
| Quarterly report(10-Q) | 2026-04-30 | 2026-03-31 |
| Major event announcement(8-K) | 2026-04-30 | 2026-04-30 |
| Shareholder voting information(DEF 14A) | 2026-04-06 | 2026-05-20 |
| Major event announcement(8-K) | 2026-03-04 | 2026-03-02 |
| Annual report(10-K) | 2026-02-12 | 2025-12-31 |
| Major event announcement(8-K) | 2026-02-12 | 2026-02-12 |
| Major event announcement(8-K) | 2026-01-12 | 2026-01-11 |
| Major event announcement(8-K) | 2025-12-11 | 2025-12-10 |
| Major event announcement(8-K) | 2025-12-03 | 2025-12-02 |
| Quarterly report(10-Q) | 2025-10-30 | 2025-09-30 |
| Major event announcement(8-K) | 2025-10-30 | 2025-10-30 |
| Major event announcement(8-K) | 2025-10-03 | 2025-09-30 |
| Major event announcement(8-K) | 2025-09-12 | 2025-09-12 |
| Major event announcement(8-K) | 2025-09-10 | 2025-09-08 |
| Quarterly report(10-Q) | 2025-07-31 | 2025-06-30 |
| Major event announcement(8-K) | 2025-07-31 | 2025-07-31 |
| Major event announcement(8-K) | 2025-06-18 | 2025-06-12 |
Coverage from the last 30 days
Hereditary Transthyretin Amyloidosis Market Insight, Epidemiology, and Market Forecast - 2036 Now Available Reveals Why a $3B Market Is Racing Toward a One-Time Curative Gene-Editing Therapy
Yahoo Finance ·
Alnylam to Webcast Presentations at Upcoming September Investor Conferences
Yahoo Finance ·
Alnylam's Latest Data Strengthen Outlook for Nucresiran, TRITON-CM, Oppenheimer Says
Yahoo Finance ·
Inceptive CEO Jakob Uszkoreit on Designing Medicines That Work Like Life Itself
Yahoo Finance ·
Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings
Yahoo Finance ·
IONS, AZN Stocks Fall On Full Data From Failed Cardiomyopathy Trial — Jefferies Sees Neutral To Negative Readthrough To ALNY
Yahoo Finance ·
AstraZeneca, Ionis data spark debate about RNA drugs’ impact on deadly heart disease
Yahoo Finance ·
Alnylam Pharmaceuticals (ALNY) Stock Looks Cheap After A 47% Fall Yet Rich On Earnings
Yahoo Finance ·
Alnylam Pharmaceuticals (ALNY) Heads To ESC With New Data, Is It A Bargain?
Yahoo Finance ·
Is Alnylam (ALNY) Turning Expanded HELIOS-B and Zilebesiran Data Into Durable Cardiovascular Leadership?
Yahoo Finance ·
Alnylam to Present New Data Reinforcing Strength in RNAi-Powered TTR Silencing and Continued Progress in Hypertension at ESC Congress 2026
Yahoo Finance ·
TG Therapeutics (TGTX) Up 15.1% Since Last Earnings Report: Can It Continue?
Yahoo Finance ·
Primary sources and further research